Fujifilm SHL partner to meet growing autoinjector demands

Through the deal with SHL, contract development and manufacturing organization (CDMO) Fujifilm seeks to improve productivity and optimize workflows for biotech and pharmaceutical companies that provide self-injection services.

The partnership aims to expand capacity of autoinjectors to up to 30 million units annually by early 2025 while encouraging SHL to advise its clients looking for CDMO services to use Fujifilm.

“We continually seek opportunities to improve patient access to medicines through meeting our customers’ needs. This partnership expands our ability to meet increased demand for autoinjector medicines primarily with SHL’s flagship Molly platform. Beginning in early 2025, we will offer pre-validated final assembly services for Molly autoinjectors with increased capacity of up to 30 million units per year,” a spokesperson for Fujifilm told BioProcess Insider.

“Once the equipment is operational and qualified (early 2025), we will offer drug substance, drug product and finished goods services from our site in Denmark. It is our hope that in the future we can extend these services to our Holly Springs, North Carolina large-scale CDMO site as well.”

Molly is a disposable, single-use auto injector device that works with syringes that have a rigid needle shield (RNS). Launched in 2016, it has supported 14 molecular entities covering at least 39 clinical indications across various therapeutic areas. Available in 1.0 mL and 2.25 mL variations, products using Molly autoinjectors have been approved and launched in a variety of standard and customized designs in 38 countries.

“Molly is a proven platform that provides a simple and high-quality solution for self-injection. However, it is just one step within the biopharma value chain. With recent trends towards sustainability and de-risking supply chains, SHL has initiated an Alliance Management program that ensures that our customers can work with our proven partners in different geographies, including Fujifilm, to achieve faster timelines and more streamlined processes along the whole value chain,” the spokesperson said.

The financials of this agreement were not disclosed.